The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of CHF 432 million ($485 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback